OOIR: Observatory of International Research

Papers

(The H4-Index of Inflammation Research is 32. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Inhibition of glycolytic reprogramming suppresses innate immune-mediated inflammation in experimental amyotrophic lateral sclerosis	240
Paradoxical expression of NRP1 in decidual stromal and immune cells reveals a novel inflammation balancing mechanism during early pregnancy	147
Kinin B1 receptor and TLR4 interaction in inflammatory response	109
Loss of TRIM24 promotes IL-10 expression via CBP/p300-dependent IFNβ1 transcription during macrophage activation	106
Beyond CYP2C19: inflammation and angiogenesis gene variants drive clopidogrel resistance in CAD patients	101
Serum from COVID-19 patients promotes endothelial cell dysfunction through protease-activated receptor 2	80
Viperin inhibits interferon-γ production to promote Mycobacterium tuberculosis survival by disrupting TBK1-IKKε-IRF3-axis and JAK-STAT signaling	78
IL10/AMPK pathway was associated with the hippocampal anti-inflammatory response to high-sugar and high-fat diet withdrawal	69
HMGB1: key mediator in digestive system diseases	65
Immune-related genetic single-nucleotide polymorphisms contribute to prognosis and response to chemotherapy in patients with acute lymphoblastic leukemia	63
Tissue-resident immune cells in the pathogenesis of multiple sclerosis	60
The NADase CD38 is a central regulator in gouty inflammation and a novel druggable therapeutic target	56
From bench to bedside: targeting lymphocyte activation gene 3 as a therapeutic strategy for autoimmune diseases	55
Association of risk of incident acne and treatment with systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis	54
Long-chain acyl-CoA synthetase 4-mediated mitochondrial fatty acid metabolism and dendritic cell antigen presentation	51
IL-33, a neutrophil extracellular trap-related gene involved in the progression of diabetic kidney disease	50
Unveiling the role of ABI3 and hub senescence-related genes in macrophage senescence for atherosclerotic plaque progression	50
The role of dietary fibre in lung inflammation: microbiota, metabolites, and immune crosstalk	50
Mitochondrial damage causes inflammation via cGAS-STING signaling in ketamine-induced cystitis	49
Single-cell hdWGCNA reveals a novel diagnostic model and signature genes of macrophages associated with chronic obstructive pulmonary disease	45
CD20+ T cells: an emerging T cell subset in human pathology	44
The role of fatty acid metabolism on B cells and B cell-related autoimmune diseases	42
Viperin deficiency promotes dendritic cell activation and function via NF-kappaB activation during Mycobacterium tuberculosis infection	42
Clinical outcomes of anti-inflammatory therapies inhibiting the NLRP3/IL-1β/IL-6/CRP pathway in coronary artery disease patients: a systemic review and meta-analysis of 37,056 individuals from 32 rand	41
A suitable model to investigate acute neurological consequences of coronavirus infection	40

Functional characterization of novel anti-DEFA5 monoclonal antibody clones 1A8 and 4F5 in inflammatory bowel disease colitis tissues	39
IL-1 receptor antagonist: etiological and drug delivery systems overview	39
Mitochondrial proteomics reveals the impact of Estrogen in enhancing energy metabolism of patient-derived fibroblast-like synoviocytes in rheumatoid arthritis	38
LncGBP9 knockdown alleviates myocardial inflammation and apoptosis in mice with acute viral myocarditis via suppressing NF-κB signaling pathway	35
Navigating the complex landscape of DPP4 inhibition in inflammation: from novel mechanisms to unresolved translational challenges	34
Antigen-specific reduced IgG inhibits cellular response in rat basophilic leukemia cells activated with multivalent antigen	32
Successful treatment of refractory erythrodermic pemphigus foliaceus with low-dose rituximab and intravenous immunoglobulin	32